New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 14, 2014
06:10 EDTLXRXLexicon achieves positive results in Type 1 diabetes clinical trial
Lexicon Pharmaceuticals announced positive, top-line results in a Phase 2 clinical trial of LX4211 in type 1 diabetes, which achieved the primary endpoint of reducing mealtime insulin use as well as several secondary endpoints, including improved glycemic control. LX4211 is an oral, first-in-class, dual inhibitor of sodium glucose transporters 1 and 2 that is designed to lower blood glucose levels through two insulin-independent mechanisms of action. In the placebo-controlled, double-blind, 28-day study, LX4211 reduced the total daily mealtime bolus insulin dose by 32% compared to 6% for placebo, while significantly improving glycemic control with a mean HbA1c reduction of 0.55% in the LX4211-treated group compared to a reduction of only 0.06% with placebo. This improvement was accompanied by significant improvement in the time spent in a glucose range of 70-180 mg/dl, a significant reduction in time in hyperglycemic range, and no increase in hypoglycemia. Multiple measures indicated that LX4211 treatment resulted in reduced variability in blood glucose levels. Overall, LX4211 was well tolerated with no discontinuations of study medication due to adverse events.
News For LXRX From The Last 14 Days
Check below for free stories on LXRX the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 12, 2014
09:14 EDTLXRXOn The Fly: Pre-market Movers
Subscribe for More Information
September 11, 2014
18:35 EDTLXRXOn The Fly: After Hours Movers
Subscribe for More Information
16:33 EDTLXRXLexicon publication of Phase 2b study shows LX4211 provides meaningful benefit
Subscribe for More Information
September 10, 2014
11:06 EDTLXRXLexicon management to meet with Jefferies
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use